People with diabetes, MI, and other cardiovascular disease were included. Data do not apply to people with kidney transplants. to a greater extent than atorvastatin 10 mg/day, in 3107 patients with CKD defined by eGFR o60 ml/min/1.73 m2 and pre-existing coronary artery disease (HR 0.68; 95% CI Serious adverse events and treatment disconti- nuation were increased in the high dose statin group for both people with and without CKD; the RRs of these adverse events were numerically higher in people with CKD as compared to those without, but no significance testing was performed. However, TNT participants were pretreated with 10 mg of atorvastatin during the run-in phase, and therefore were preselected for atorvastatin tolerance. In addition, the mean eGFR among TNT participants with CKD was , and patients with heavy proteinuria were excluded. Therefore, whether these findings apply to the broader population of people with CKD is uncertain. Given the potential for toxicity with higher doses of statins and the relative lack of safety data, the Work Group suggests that prescription of statins in people with eGFR o60 ml/ or RRT should be based on regimens and doses that have been shown to be beneficial in randomized trials done specifically in this population (Table 4). Patients with progressive renal dysfunction who are tolerating an alter- native regimen do not necessarily need to be switched to a regimen described in Table 4, although dose reduction may be prudent in patients with severe kidney dysfunction who are receiving very aggressive regimens. Given less concern about drug toxicity in the setting of better kidney function, (and no history of kidney transplantation) may be treated with any statin regimen that is approved for use in the general population. 